# Emyria Ltd

11:56 11 Sep 2020

## Emerald Clinics set to benefit from interim TGA decision to down schedule CBD

Emerald Clinics Ltd (ASX:EMD) welcomes the interim decision from Australia's Therapeutic Goods Administration (TGA) that recommends low dose cannabidiol, or CBD, become a Schedule 3 medicine on the Australian Register of Therapeutic Goods (ARTG).

The interim ruling outlined the process for low dose CBD to be registered as a Schedule 3 medicine at the 60mg/day limit.

Registration of low dose CBD would require a full submission to the TGA and high-quality clinical evidence to support safety and effectiveness.

The TGA interim decision could allow patients to purchase low dose CBD as a pharmacist only or over-the-counter medication for specific indications.

Advertising to consumers would not be permitted and higher doses of CBD and other cannabinoid medicines would still require a prescription from a medical practitioner.

**"Encouraged by meaningful commitment"**

Emerald Clinics' chief executive officer Dr Michael Winlo said: "Regulators play an important role ensuring medicines are safe and effective before they are available to patients which is why they require independent and high-quality clinical evidence to support their recommendations.

"Emerald exists to generate product-specific real-world evidence packages and insights that can support regulators, like the TGA and others involved in these decisions around the globe, together with developers of CBD and other new treatments.

"We are encouraged by this meaningful commitment to bring evidence-based, innovative therapies to patients."

The TGA will undertake a second consultation period with a closing deadline of October 13 and expects to make a final decision on February 1.

| | |
|---|---|
| **Price:** | 0.077 |
| **Market Cap:** | $16.28 m |

**1 Year Share Price Graph**


### Share Information

| | | |
|---|---|---|
| **Code:** | | EMD |
| **Listing:** | | ASX |
| **52 week** | **High** | **Low** |
| | **0.155** | **0.038** |
| **Sector:** | | **Pharma & Biotech** |
| **Website:** | | **www.emyria.com** |

**Company Synopsis:**

*Emyria Ltd (ASX:EMD) is a Real-World Evidence data company using its network of specialist clinical services and purpose-built, remote patient monitoring technologies and data platforms to accelerate the development and registration of new treatments and facilitate the implementation of valuable new care models.*

**action@proactiveinvestors.com.au**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

## No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars ($25,000).